IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Industrial Biotech

Lonza Signs Manufacturing Deal with Biopharma Firm

11:31 AM MDT | June 26, 2009

Lonza says it has signed a deal to produce therapeutic monoclonal antibody Anthim for biopharmaceutical company Elusys Therapeutics (Pine Brook, NJ). Anthim, which is in late-stage development, can be used to treat anthrax infection. Lonza says it will provide process development services and manufacturing capacity, using its GS Gene Expression System, under the deal. Elusys develops antibody therapeutics for treatment of infectious disease. Elusys has been active in the development of bio-warfare countermeasures since 2001 and has worked with the U.S. government...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.



Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.

 














 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa